Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
収録刊行物
-
- The Lancet
-
The Lancet 394 (10216), 2271-2281, 2019-12
Elsevier BV